menu

Slide

Investments in unique diagnostic technologies for the era of precision medicine

Scroll Down
Scroll Down
Hummingbird Diagnostics Publishes Study of miRisk as a Predictor of Immunotherapy Efficacy in Advanced-Stage NSCLC

READ MORE

Hummingbird Diagnostics Developing miRNA-Based Immunotherapy Predictor on Heels of Positive Study

READ MORE

Blood-based microRNA signature may predict survival in immunotherapy-treated NSCLC

READ MORE

Hummingbird Diagnostics Announces Publication of Study on the Utility of miRisk, a Blood-based microRNA Analysis, to Predict Overall Survival for Advanced Non-Small Cell Lung Cancer in npj Precision Oncology

READ MORE

GreyBird Ventures

is named after the arctic tern, a bird that migrates 71,000 km annually. As they can live for 30 years, this is the lifetime equivalent of three trips to the moon and back. Not bad for a 100 gram bird. We strive to emulate its size to performance ratio as well as its global reach.

MEET THE PEOPLE

For additional information, please contact: greybird@greybirdventures.com

DISCLAIMER